Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Home
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Next Post
Previous Post
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
March 26, 2023
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Response to Treatment With
nab
-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECTÂ
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of
nab
-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
and
TSC2
Read More
Stephen Rodin, JD
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Patients With Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1
KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor
nab
-Sirolimus Show Improved Antitumor Activity
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009,
nab
-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.